Trials / Completed
CompletedNCT00174486
Assessment Of Duration Of Action, Safety & Toleration Of UK369,003 and Cialis In Patients With Erectile Dysfunction
A Double Blind, Placebo Controlled, Parallel Group, Multicenter Study To Assess The Duration Of Action, Safety And Toleration Of Differing Doses and Combinations Of Immediate and Modified Release Formulations Of UK-369,003 and Cialis Compared To Placebo In Adult Male Subjects With Erectile Dysfunction
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Assessment of duration of action, safety \& toleration of different formulations and doses of UK-369,003 and Cialis in patients with male erectile dysfunction. Patients should have previously been on PDE5 inhibitors and have been respondents to the drug. Duration of treatment is 4 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | UK0369,003 | |
| DRUG | Cialis (Tadalafil) |
Timeline
- Start date
- 2005-02-01
- Completion
- 2005-06-01
- First posted
- 2005-09-15
- Last updated
- 2006-07-25
Source: ClinicalTrials.gov record NCT00174486. Inclusion in this directory is not an endorsement.